Walleye Capital LLC Iveric Bio, Inc. Transaction History

Walleye Capital LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $2.04 Million - $3.08 Million	-77,773 Reduced 54.17%	65,805 $2.59 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $5.81 Million - $7.64 Million	-311,237 Reduced 68.43%	143,578 $3.49 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $3.23 Million - $4.48 Million	-187,136 Reduced 29.15%	454,815 $9.74 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $270,588 - $535,131	28,786 Added 4.69%	641,951 $11.5 Million
Q2 2022 Aug 08, 2022	BUY	$9.12 - $18.9 $738,902 - $1.53 Million	81,020 Added 15.23%	613,165 $5.9 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $4.12 Million - $5.71 Million	339,172 Added 175.76%	532,145 $8.96 Million
Q4 2021 Mar 03, 2022	BUY	$13.83 - $18.78 $2.67 Million - $3.62 Million	192,973 New	192,973 $3.23 Million
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $439,400 - $1.09 Million	-62,150 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $353,633 - $445,615	62,150 New	62,150 $392,000
Q2 2020 Aug 14, 2020	SELL	$3.06 - $6.6 $49,143 - $105,996	-16,060 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.83 - $8.44 $45,449 - $135,546	16,060 New	16,060 $55,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.